Working together to prevent blindness
Odylia Therapeutics is a 501(c)(3) corporation combining the expertise and experience of our founders, board members, and partner organizations to fill a unique void in moving ultra-rare inherited retinal diseases from science to humans. Our organization focuses on those diseases that would typically have limited commercial appeal and would be neglected, even though the science is available to make significant progress.
Board of Directors
Luk Vandenberghe, PhD
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear
Scott Dorfman, BBA
CEO, Odylia Therapeutics
Matthew Pletcher, PhD
RDH12 Fund for Sight
Emil Kakkis, MD, PhD
President and Founder
Ultragenyx Pharmaceutical Inc
Advisory Board
Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear
Joy Cavagnaro, PhD
President, Access Bio
Jean Bennett, MD, PhD
Professor, Perelman School of Medicine
University of Pennsylvania
Alberto Auricchio, PhD
Associate Professor of Medical Genetics
“Federico II” University Napoli
Principal Investigator, TIGEM
Alan Spiro, BA, PhD, JD
Partner, ExSight Ventures
Gregory Robinson, PhD
Chief Scientific Officer, Akouos
Tiansen Li, PhD
Senior Investigator, Retinal Cell Biology and Degeneration Section, NEI
Founding Members
Luk Vandenberghe, PhD
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear
Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear
Scott Dorfman, BBA
CEO, Odylia Therapeutics
John Fernandez, MS
President and CEO,
Massachusetts Eye and Ear
Joan Miller, MD
Chief of Ophthalmology,
Massachusetts Eye and Ear